An interventional study of Hand fist -clenching exercise and topical Aloe vera gel in Peripheral Intravenous Catheter-related Phlebitis, Hand Fist -Clenching and Prevention, sponsored by Fatima Hussein Ali Hamad. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Fatima Hussein Ali Hamad · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate and compare the effectiveness of hand fist-clenching exercises versus topical Aloe Vera gel in preventing peripheral intravenous catheter (PIVC)-related phlebitis among adult patients. Phlebitis is a common complication associated with IV therapy. The study will assess adult patients admitted to the internal medicine wards to determine which preventive intervention is more effective in reducing the incidence of phlebitis."
47 studies on the registry are indexed under Phlebitis; 10 are open to participants now.
This study's planned enrollment of 60 is below the median of 123 across 39 interventional studies indexed under Phlebitis.
Browse Phlebitis studies →This is the only study on the registry with Fatima Hussein Ali Hamad as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Agree to participate in the study.
-
Exclusion Criteria:Participants with:
Patients requiring immediate removal of the peripheral intravenous catheter before completion of the observation period.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Hand fist -clenching exercise
Other: topical Aloe vera gel
Initiation and Patient Education: Hand fist-clenching exercise will be initiated immediately after insertion of the peripheral intravenous catheter (PIVC). The exercise will be taught to the patient by the researcher, and the procedure will be demonstrated to ensure that the patient understands how to perform it. Exercise Procedure: The patient will perform the exercise by making a fist with the hand in which the PIVC is inserted. The fist will be maintained for 30 seconds to 1 minute for each repetition. Frequency and Duration: The exercise will be performed approximately 20 times during each session, with each session lasting 5-10 minutes. The exercise will be performed twice daily. Supervision: The patient's performance of the exercise will be conducted under the supervision of the researcher.
Catheter Insertion Site Preparation and Insertion * Within the aloe vera gel intervention group, the intended catheterinsertion site underwent initial disinfection using a 70% ethyl alcoholsolution. * Subsequent to the complete evaporation of the alcohol, the nurseintroduced the angiocatheter , and its position was stabilized throughthe application of an angiocatheter securement adhesive. * Finally, 0.5 cc of aloe vera gel was topically applied to the superioraspect of the aforementioned adhesive.. 2\. Follow-up and Assessment * The insertion sites were monitored every 12 hours for a period following catheter placement to detect any indications of phlebitis,which were documented dichotomously (Yes/No). 3\. Standardization of Catheter Insertion * The angiocatheter insertions were executed by a registered nurse with a decade of professional experience within the internal medicine department.
incidence of peripheral intravenous catheter -related Phlebitis
The incidence of phlebitis will be assessed using the Visual Infusion Phlebitis (VIP) scale. The VIP scale ranges from 0 (no signs of phlebitis) to 5 (advanced stage of thrombophlebitis). A score of 1 or greater indicates the occurrence of phlebitis
Time frame: assessed twice daily for 48 hours
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 21 non-industry interventional studies with no phase under Phlebitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 3 months is below that.
Counting every sponsor, half of 21 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.